FrankSLiebermanMD

Neurology • Pittsburgh, PA

Neurooncology

Professor of Neurology, Neurosurgery and Medicine (Medical Oncology) University of Pittsburgh School of Medicine

Join to view full profile

Dr. Lieberman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lieberman's full profile

Already have an account?

Office
3471 Fifth Avenue
Pittsburgh, PA 15213
Phone+1 412-641-1000

Fax+1 412-641-1221
Is this information wrong?

Education & Training

University of ChicagoNeuroimmunology, 1983 - 1985
University of ChicagoResidency, Neurology, 1980 - 1983
University of ChicagoInternship, Internal Medicine, 1979 - 1980
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1979

Certifications & Licensure

PA State Medical License 1999 - 2024
NJ State Medical License 1985 - 1991
IL State Medical License 1980 - 1987
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors Start of enrollment: 2001 Oct 09
Completed
Phase 2
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2004 Nov 01
Completed
Phase 2
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas Start of enrollment: 2009 Jan 01
Completed
Early Phase 1
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas Start of enrollment: 2009 Apr 01
Completed
Early Phase 1
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Apr 15
Completed
Phase 3
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2010 Jul 01
Completed
Phase 2
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Start of enrollment: 2012 May 31
Completed
Phase 1
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas Start of enrollment: 2012 Oct 01
Completed
Early Phase 1
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2013 Aug 19
Active, not recruiting
Phase 1
Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Start of enrollment: 2014 May 01
Completed
Phase 2
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
Roles: Contact
Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma Start of enrollment: 2019 Oct 22
Completed
Early Phase 1
Roles: Contact
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma.
Plute, T., Felker, J. T., Stephanie M Casillo, Taylor A Gatesman, Akanksha Chilukuri, Srinidhi Varadharajan, Brenden J Johnson, Daniel R David Premkumar, Esther P Jane...> ;Cell Reports. 2024 Jan 23
A multi-site phase I trial of Veliparib with standard radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).
Lawrence Kleinberg, Xiaobu Ye, Jeff Supko, Glen H J Stevens, Hui-Kuo Shu, Tom Mikkelsen, Frank Lieberman, Glenn J Lesser, Emerson Lee, Stuart A Grossman> ;Journal of Neuro-Oncology. 2023 Dec 1
2 citations
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Michal Nisnboym, Sarah R Vincze, Zujian Xiong, Chaim T Sneiderman, Rebecca A Raphael, Bo Li, Ambika P Jaswal, ReidAnn E Sever, Kathryn E Day, Joseph D LaToche, Lesley ...> ;Cancer Research Communications. 2023 Jul 1
1 citations
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.
Golbourn, B., Halbert, M., Halligan, K., Varadharajan, S., Krug, B., Mbah, N., Kabir, N., Stanton, A., Locke, A., Casillo, S., Zhao, Y., Sanders, L., Cheney, A., Mulle...> ;Nature Cancer. 2022 Jul 1
14 citations
Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.
Felker, J. T., Brian J Golbourn, Matthew E Halbert, Katharine Halligan, Srinidhi Varadharajan, Brian Krug, Nneka E Mbah, Nisha Kabir, Ann-Catherine J Stanton, Abigail ...> ;Nature Cancer. 2022 May 1
The Added Value of Family Caregivers' Level of Mastery in Predicting Survival of Glioblastoma Patients: A Validation Study.
Florien W. Boele, Jason Weimer, Amir H Zamanipoor Najafabadi, Louise Murray, Charles W. Given, Barbara A. Given, Heidi S. Donovan, Jan Drappatz, Frank S. Lieberman, Pa...> ;Cancer Nursing. 2021 Sep 30
28 citations
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Itay Raphael, Rajeev Kumar, Lauren McCarl, Karsen Shoger, Lin Wang, Poorva Sandlesh, Chaim T Sneiderman, Jordan Allen, Shuyan Zhai, Marissa Lynn Campagna, Alexandra Fo...> ;Frontiers in Immunology. 2021 May 7
24 citations
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Mark R. Gilbert, Ying Yuan, Jimin Wu, Tito R. Mendoza, Elizabeth Vera, Antonio Omuro, Frank S. Lieberman, H. Ian Robins, Elizabeth R. Gerstner, Jing Wu, Patrick Y. Wen...> ;Neuro-Oncology. 2021 Mar 25
14 citations
A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma
David M. Peereboom, Xiaobu Ye, Tom Mikkelsen, Glenn J. Lesser, Frank S. Lieberman, H. Ian Robins, Manmeet Ahluwalia, Andrew E. Sloan, Stuart A. Grossman> ;Neurosurgery. 2021 Jan 13
26 citations
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Eudocia Q. Lee, Michael Weller, Joohee Sul, Stephen J Bagley, Solmaz Sahebjam, Martin J. van den Bent, Manmeet Ahluwalia, Jian Campian, Evanthia Galanis, Mark R. Gilbe...> ;Neuro-Oncology. 2020 May 15
6 citations
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02
Huanwen Chen, John G. Kuhn, Kathleen R. Lamborn, Lauren E. Abrey, Lisa M. DeAngelis, Frank S. Lieberman, H. Ian Robins, Susan M. Chang, W. K. Alfred Yung, Jan Drappatz...> ;Neuro-Oncology Advances. 2020 Jan 1
5 citations
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.
H. Ian Robins, Jens Eickhoff, Mark R. Gilbert, Terri S. Armstrong, Wenyin Shi, John de Groot, Christopher J. Schultz, Grant K. Hunter, Egils Valeinis, Mack Roach, Emad...> ;Neuro-Oncology Practice. 2019 Dec 7
4 citations
Psychometric Evaluation of the Caregiver Needs Screen in Neuro-Oncology Family Caregivers.
Florien W. Boele, Lauren Terhorst, Jennifer Prince, Heidi S. Donovan, Jason Weimer, Paula R. Sherwood, Frank S. Lieberman, Jan Drappatz> ;Journal of Nursing Measurement. 2019 Aug 1
9 citations
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Frank S. Lieberman, Meihua Wang, H. Ian Robins, Christina I. Tsien, Walter J. Curran, Maria Werner-Wasik, Ryan P. Smith, Christopher J. Schultz, Alan C. Hartford, Peix...> ;International Journal of Radiation Oncology, Biology, Physics. 2019 Mar 15
3 citations
Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
Michael S. Dressen, Ashok Muthukrishnan, Tyson R. Tragon, Frank S. Lieberman, James M. Mountz> ;Clinical Nuclear Medicine. 2019 Jan 1
27 citations
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therap...
Deborah T. Blumenthal, Minhee Won, Minesh P. Mehta, Mark R. Gilbert, Paul D. Brown, Felix Bokstein, David G Brachman, Maria Werner-Wasik, Grant K. Hunter, Egils Valein...> ;Neuro-Oncology. 2018 Jun 18
24 citations
Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Megan Mantica, Ashley Pritchard, Frank S. Lieberman, Jan Drappatz> ;Journal of Neuro-Oncology. 2018 May 19
9 citations
Fast 3D rosette spectroscopic imaging of neocortical abnormalities at 3 T: Assessment of spectral quality.
Claudiu Schirda, Tiejun Zhao, Victor E. Yushmanov, Yoojin Lee, Gena Ghearing, Frank S. Lieberman, Ashok Panigrahy, Hoby P. Hetherington, Jullie W. Pan> ;Magnetic Resonance in Medicine. 2018 May 1
2 citations
Chemotherapy of Oligodendrogliomas
Jan Drappatz, Frank S. Lieberman> ;Progress in Neurological Surgery. 2018 Jan 1
1286 citations
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp, Sophie Taillibert, Andrew A. Kanner, William L. Read, David M. Steinberg, Benoit Lhermitte, Steven A. Toms, Ahmed Idbaih, Manmeet Ahluwalia, Karen Fink, F...> ;JAMA. 2017 Dec 19
58 citations
Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.
Frank S. Lieberman> ;F1000research. 2017 Oct 26
19 citations
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02
Phioanh L. Nghiemphu, Victoria Ebiana, Patrick Y. Wen, Mark R. Gilbert, Lauren E. Abrey, Frank S. Lieberman, Lisa M. DeAngelis, H. Ian Robins, W. K. Alfred Yung, Susan...> ;Journal of Neuro-Oncology. 2018 Jan 1
5 citations
Long-term recurrence of dysembryoplastic neuroepithelial tumor: Clinical case report.
Daniel A Tonetti, WilliamJ Ares, RMark Richardson, RonaldL Hamilton, FrankS Lieberman> ;Surgical Neurology International. 2017 Jul 11
36 citations
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas
Matthias Holdhoff, Xiaobu Ye, Jeffrey G. Supko, Louis B. Nabors, Arati Desai, Tobias Walbert, Glenn J. Lesser, William L. Read, Frank S. Lieberman, Martin A. Lodge, Je...> ;Neuro-Oncology. 2017 Jun 1
18 citations
Neuro-oncology family caregivers’ view on keeping track of care issues using eHealth systems: it’s a question of time
Florien W. Boele, Cornelia F. van Uden-Kraan, Karen Hilverda, Jason Weimer, Heidi S. Donovan, Jan Drappatz, Frank S. Lieberman, Irma M. Verdonck-de Leeuw, Paula R. She...> ;Journal of Neuro-Oncology. 2017 May 26
Join now to see all

Press Mentions

Comprehensive Genetic Profiling Possible for Central Nervous System TumorsFebruary 11th, 2016
Test Rapidly, Accurately Profiles Genetics and Treatment of Brain TumorsFebruary 1st, 2016

Grant Support

Nabtc Member Institution Grant (Ucsf Project Leader)National Cancer Institute2002–2008
Phi/Ii Trial Of R115777 In PTS W/Recurrent Malignant GliomaNational Center For Research Resources2005
PH II TRL Of EMD 121974 Rcurrent Glioblastoma Clin Trial W/Tissue Correlate RESPNational Center For Research Resources2005
PH I/II Trial OSI-774 PTS W/Recurr Malig Gliomas &Malig Gliomas Post RadiatnNational Center For Research Resources2005
Phi/Ii ZD1839 In Subj W/Recurr. Malig. Glioma MeningiomasNational Center For Research Resources2004
Phi/Ii Trial Cpt-11/Temozolomide In Malignant GliomaNational Center For Research Resources2004
PH I/II Trial OSI-774 PTS W/Recurr. Malig. GliomasNational Center For Research Resources2004
Gene Therapy For Recurrent Glioblastoma Multiforme--Phase I TrialNational Center For Research Resources1998–2002